Literature DB >> 23352778

Resolution of left bundle branch block-induced cardiomyopathy by cardiac resynchronization therapy.

Caroline Vaillant1, Raphaël P Martins, Erwan Donal, Christophe Leclercq, Christophe Thébault, Nathalie Behar, Philippe Mabo, Jean-Claude Daubert.   

Abstract

OBJECTIVES: The study sought to describe a specific syndrome characterized by isolated left bundle branch block (LBBB) and a history of progressive left ventricular (LV) dysfunction, successfully treated by cardiac resynchronization therapy (CRT).
BACKGROUND: Isolated LBBB in animals causes cardiac remodeling due to mechanical dyssynchrony, reversible by biventricular stimulation. However, the existence of LBBB-induced cardiomyopathy in humans remains uncertain.
METHODS: Between 2007 and 2010, 375 candidates for CRT were screened and retrospectively included in this study if they met all criteria of a pre-defined syndrome, including: 1) history of typical LBBB for >5 years; 2) LV ejection fraction (EF) >50%; 3) decrease in LVEF to <40% and development of heart failure (HF) to NYHA functional class II to IV over several years; 4) major mechanical dyssynchrony; 5) no known etiology of cardiomyopathy; and 6) super-response to CRT with LVEF >45% and decrease in NYHA functional class at 1 year.
RESULTS: The syndrome was identified in 6 patients (1.6%), 50.5 years of age on average at the time of LBBB diagnosis. HF developed over a mean of 11.6 years. At the time of referral, Doppler echocardiograms showed major mechanical dyssynchrony at left atrioventricular, interventricular, and left intraventricular levels. During CRT, NYHA functional class decreased, LV dimensions normalized and mechanical dyssynchrony was nearly resolved in all patients, and mean LVEF increased from 31 ± 12% to 56 ± 8% (p = 0.027).
CONCLUSIONS: These observations support the existence of a specific LBBB-induced cardiomyopathy resolved by CRT. Its prevalence, time course, and risk factors need to be prospectively studied.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23352778     DOI: 10.1016/j.jacc.2012.10.053

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

1.  Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study.

Authors:  Yonathan F Melman; Ravi Shah; Kirsty Danielson; Junjie Xiao; Bridget Simonson; Andreas Barth; Khalid Chakir; Gregory D Lewis; Zachary Lavender; Quynh A Truong; Andre Kleber; Ranendra Das; Anthony Rosenzweig; Yaoyu Wang; David Kass; Jagmeet P Singh; Saumya Das
Journal:  Circulation       Date:  2015-05-20       Impact factor: 29.690

2.  Myocardial recovery after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.

Authors:  Norman C Wang; Aliza Hussain; Evan C Adelstein; Andrew D Althouse; Michael S Sharbaugh; Sandeep K Jain; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-09-28       Impact factor: 1.468

3.  Is exercise stress echocardiography useful in patients with suspected obstructive coronary artery disease who have resting left bundle branch block?

Authors:  Bo Xu; Laura Dobson; Philip M Mottram; Arthur Nasis; James Cameron; Stuart Moir
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

4.  Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy.

Authors:  Gregory Sinner; Hesham R Omar; You W Lin; Samy C Elayi; Maya E Guglin
Journal:  Clin Cardiol       Date:  2018-12-15       Impact factor: 2.882

5.  Sex-specific clinical outcomes after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.

Authors:  Norman C Wang; Ure Mezu-Chukwu; Evan C Adelstein; Andrew D Althouse; Michael S Sharbaugh; Sandeep K Jain; Alaa A Shalaby; Andrew H Voigt; Samir Saba
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-03-27       Impact factor: 1.468

Review 6.  Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling.

Authors:  Edward Sze; James P Daubert
Journal:  J Interv Card Electrophysiol       Date:  2018-07-17       Impact factor: 1.900

7.  Evaluation of super-responders to cardiac resynchronization therapy in the presence of left bundle branch block and absence of scar in the posterolateral wall of the left ventricle.

Authors:  Izaias Marques de Sá Junior; José Carlos Pachón Mateos; Juan Carlos Pachón Mateos; Remy Nelson Albornoz Vargas
Journal:  Am J Cardiovasc Dis       Date:  2020-04-15

8.  Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block.

Authors:  Edward Sze; Zainab Samad; Allison Dunning; Kristen Bova Campbell; Zak Loring; Brett D Atwater; Karen Chiswell; Joseph A Kisslo; Eric J Velazquez; James P Daubert
Journal:  J Am Coll Cardiol       Date:  2018-01-23       Impact factor: 24.094

9.  Rational and design of EuroCRT: an international observational study on multi-modality imaging and cardiac resynchronization therapy.

Authors:  Erwan Donal; Victoria Delgado; Julien Magne; Chiara Bucciarelli-Ducci; Christophe Leclercq; Bernard Cosyns; Marta Sitges; Thor Edvardsen; Elif Sade; Ivan Stankovic; Eustachio Agricola; Maurizio Galderisi; Patrizio Lancellotti; Alfredo Hernandez; Sven Plein; Denisa Muraru; Ehud Schwammenthal; Gerhard Hindricks; Bogdan A Popescu; Gilbert Habib
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2017-10-01       Impact factor: 6.875

10.  Left bundle-branch block is associated with asimilar dyssynchronous phenotype in heart failure patients with normal and reduced ejection fractions.

Authors:  Daniel J Friedman; Kasper Emerek; Joseph Kisslo; Peter Søgaard; Brett D Atwater
Journal:  Am Heart J       Date:  2020-10-22       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.